Drug Trial Radar · NCT03471351
Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL
Last checked: Nov 19, 2026Latest source record: Dec 27, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
2
Actual
Start
Jul 18, 2018
Primary completion
Feb 13, 2019
Study completion Feb 13, 2019
Sponsor
- Lead sponsor
- Rhizen Pharmaceuticals SAIndustry
- Sponsor type
- Industry
- First posted
- Mar 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) for Tenalisib in combination with Pembrolizumab in patients with cHL.
Conditions
- Classical Hodgkin Lymphoma
Interventions
TenalisibDrug
Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W
PembrolizumabBiological
Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD) for Tenalisib in combination with Pembrolizumab in patients with cHLTime frame: 21 days
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of Chicago
Chicago, Illinois
Rhizen Pharmaceuticals investigational trial site; Karmanos Cancer Institute,
Detroit, Michigan
University of Washington
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.